^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/12/2011
Excerpt:
Yervoy as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults, and adolescents 12 years of age and older.
Source:
Excerpt:
YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for:...Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older.
Source:
Published date:
01/26/2022
Excerpt:
Melanoma: Cutaneous...SYSTEMIC THERAPY FOR METASTATIC AND URESECTABLE DISEASE...SECOND-LINE OR SUBSEQUENT THERAPY...Other regimens...Ipilimumab
Source:
Title:
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006
Published date:
10/25/2021
Excerpt:
Median OS from ipilimumab initiation was 9.8 months....Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.
DOI:
https://doi.org/10.1016/j.annonc.2021.10.010
Trial ID:
Source:
Title:
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
Excerpt:
...in the ipilimumab group, as compared with 30.3% in the placebo group (hazard ratio for recurrence or death, 0.76; 95% confidence interval [CI], 0.64 to 0.89; P<0.001)...The rate of overall survival at 5 years was 65.4% in the ipilimumab group, as compared with 54.4% in the placebo group (hazard ratio for death, 0.72; 95.1% CI, 0.58 to 0.88; P=0.001)....stage III melanoma, ipilimumab at a dose of 10 mg per kilogram resulted in significantly higher rates of recurrence-free survival, overall survival, and distant metastasis-free survival than placebo...
DOI:
10.1056/NEJMoa1611299
Trial ID:
